Success Metrics

Clinical Success Rate
85.1%

Based on 205 completed trials

Completion Rate
85%(205/241)
Active Trials
41(13%)
Results Posted
54%(111 trials)
Terminated
36(11%)

Phase Distribution

Ph phase_4
21
7%
Ph early_phase_1
1
0%
Ph not_applicable
12
4%
Ph phase_1
94
30%
Ph phase_2
114
36%
Ph phase_3
73
23%

Phase Distribution

95

Early Stage

114

Mid Stage

94

Late Stage

Phase Distribution315 total trials
Early Phase 1First-in-human
1(0.3%)
Phase 1Safety & dosage
94(29.8%)
Phase 2Efficacy & side effects
114(36.2%)
Phase 3Large-scale testing
73(23.2%)
Phase 4Post-market surveillance
21(6.7%)
N/ANon-phased studies
12(3.8%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

82.0%

205 of 250 finished

Non-Completion Rate

18.0%

45 ended early

Currently Active

41

trials recruiting

Total Trials

315

all time

Status Distribution
Active(52)
Completed(205)
Terminated(45)
Other(13)

Detailed Status

Completed205
Terminated36
Recruiting28
Active, not recruiting13
unknown13
Withdrawn9

Development Timeline

Analytics

Development Status

Total Trials
315
Active
41
Success Rate
85.1%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (0.3%)
Phase 194 (29.8%)
Phase 2114 (36.2%)
Phase 373 (23.2%)
Phase 421 (6.7%)
N/A12 (3.8%)

Trials by Status

active_not_recruiting134%
completed20565%
terminated3611%
enrolling_by_invitation31%
recruiting289%
unknown134%
not_yet_recruiting83%
withdrawn93%

Recent Activity

Clinical Trials (315)

Showing 20 of 315 trialsScroll for more
NCT07568678Phase 1

A Phase 1, Multiple Ascending Dose Study to Evaluate HMS1005 in Participants With Type 2 Diabetes

Recruiting
NCT06727552Phase 2

A Study of Barzolvolimab in Patients With Atopic Dermatitis

Active Not Recruiting
NCT04649242Phase 3

Randomized Study in Children and Adolescents With Migraine: Acute Treatment

Recruiting
NCT06517758Phase 3

A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.

Recruiting
NCT07173751Phase 3

ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

Recruiting
NCT05774184Phase 2

A Study of CDX-0159 in Patients With Eosinophilic Esophagitis

Completed
NCT07554885Not Applicable

Nutritional Therapy Plus Corticosteroids for Immune Checkpoint Inhibitor-Related Pneumonitis

Not Yet Recruiting
NCT07217665Phase 2

The Progressive Supranuclear Palsy Clinical Trial Platform - Regimen A: AADvac1

Not Yet Recruiting
NCT07264283Phase 2

The Progressive Supranuclear Palsy Clinical Trial Platform - Regimen B: LM11A-31

Not Yet Recruiting
NCT07189390Phase 2

The Bloom Infant Probiotic (BIP) Study

Not Yet Recruiting
NCT06572228Phase 4

Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma

Recruiting
NCT05646381Phase 2

A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis

Recruiting
NCT07520110Phase 3

Metformin to Attenuate Progressive Respiratory Decline in Idiopathic Pulmonary Fibrosis

Not Yet Recruiting
NCT06148311Phase 2

Dexmedetomidine Sublingual Film for the Ambulatory Treatment of Hyperadrenergic Autonomic Crisis in Patients With Familial Dysautonomia

Enrolling By Invitation
NCT07375758Phase 1

A Study of MIL116 in Healthy Participants and Patients With IgA Nephropathy.

Recruiting
NCT07266402Phase 3

A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)

Recruiting
NCT06445023Phase 3

A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria

Active Not Recruiting
NCT06455202Phase 3

A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)

Active Not Recruiting
NCT06784349Phase 1

ALN-APOC3 in Adult Participants With Dyslipidemia

Completed
NCT05772546Phase 2

Avatrombopag vs. Placebo for CIT in GI Malignancies

Active Not Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
315